Aclaris Therapeutics, Inc.

Contributing Author

Recent Articles by Aclaris Therapeutics, Inc.

Jan-27	Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) ACRS GlobeNewswire
Jan-12	Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 ACRS GlobeNewswire
Jan-06	Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development ACRS GlobeNewswire
Dec-19	Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) ACRS GlobeNewswire
Nov-25	Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference ACRS GlobeNewswire
Nov-06	Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update ACRS GlobeNewswire
Oct-29	Aclaris Therapeutics to Participate in Three November Healthcare Conferences ACRS GlobeNewswire
Sep-30	Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025 ACRS GlobeNewswire
Sep-09	Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress ACRS GlobeNewswire
Aug-27	Aclaris Therapeutics to Participate in Two September Healthcare Conferences ACRS GlobeNewswire
Aug-07	Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update ACRS GlobeNewswire
Jul-29	Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints ACRS GlobeNewswire
Jul-28	Aclaris Therapeutics Announces Leadership Transition ACRS GlobeNewswire
Jun-30	Aclaris Therapeutics Added to the Russell 2000 and Russell 3000 Indexes ACRS GlobeNewswire
Jun-26	Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference ACRS GlobeNewswire
Jun-23	Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 ACRS GlobeNewswire
Jun-02	Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis ACRS GlobeNewswire
May-28	Aclaris Therapeutics to Participate in Two June Healthcare Conferences ACRS GlobeNewswire
May-09	Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series ACRS GlobeNewswire
May-08	Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update ACRS GlobeNewswire

Aclaris Therapeutics, Inc.

Recent Articles by Aclaris Therapeutics, Inc.

Upgrade your FINVIZ experience